Central Nervous System Involvement of Rhabdomyosarcoma: A Single Institution Experience

J Pediatr Hematol Oncol. 2019 Mar;41(2):152-154. doi: 10.1097/MPH.0000000000001166.

Abstract

The incidence of central nervous system (CNS) involvement in patients with rhabdomyosarcoma (RMS) is low, and the outcome is dismal. We present a single institution analysis of CNS involvement of pediatric RMS. In 59 patients, the prevalence of CNS involvement was 11.9% (7 patients), higher than prior reports. Of the 6 deaths from disease, all had rapid progression, with a median survival of 14 days. The higher incidence could be secondary to treatment modifications or more sensitive detection. These findings are useful for decisions at the time of CNS involvement and could lead to modifications for future RMS clinical trials.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Central Nervous System Neoplasms* / mortality
  • Central Nervous System Neoplasms* / therapy
  • Child
  • Child, Preschool
  • Disease-Free Survival
  • Female
  • Humans
  • Male
  • Prevalence
  • Retrospective Studies
  • Rhabdomyosarcoma* / mortality
  • Rhabdomyosarcoma* / therapy
  • Survival Rate